Focus: Rein Therapeutics is a public biotech company focused on perpetually active peptides across nephrology, respiratory, and oncology indications. With 5,000+ employees, the company operates at mid-cap scale but faces critical financial headwinds.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Rein Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Rein Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rein Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Rein Therapeutics (NASDAQ: RNTX) raises $50M, funds IPF trial into 2028 - Stock Titan
Rein Therapeutics (NASDAQ: RNTX) raises $50M, funds IPF trial into 2028 Stock Titan
Rein Therapeutics (NASDAQ: RNTX) to sell 50M shares, nets ~$46.1M - Stock Titan
Rein Therapeutics (NASDAQ: RNTX) to sell 50M shares, nets ~$46.1M Stock Titan
Rein Therapeutics prices $50 million public offering at $1 - Investing.com
Rein Therapeutics prices $50 million public offering at $1 Investing.com
Rein's $50M stock sale backs Phase 2 lung fibrosis study - Stock Titan
Rein's $50M stock sale backs Phase 2 lung fibrosis study Stock Titan
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock - GlobeNewswire
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock GlobeNewswire
RNTX Ownership | REIN THERAPEUTICS INC (NASDAQ:RNTX) - ChartMill
RNTX Ownership | REIN THERAPEUTICS INC (NASDAQ:RNTX) ChartMill
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
LTI-03 peptide demonstrates anti-fibrotic activity in ex vivo lung slices from patients with IPF.
Caveolin Scaffolding Domain (CSD) Peptide LTI-2355 Modulates the Phagocytic and Synthetic Activity of Lung-Derived Myeloid Cells in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F).
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo